Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Jul 19 04:00PM ET
72.56
Dollar change
-0.95
Percentage change
-1.29
%
IndexNDX, S&P 500 P/E202.29 EPS (ttm)0.36 Insider Own0.09% Shs Outstand1.25B Perf Week3.72%
Market Cap90.40B Forward P/E10.16 EPS next Y7.14 Insider Trans-1.25% Shs Float1.24B Perf Month14.90%
Income484.00M PEG37.56 EPS next Q1.59 Inst Own85.56% Short Float1.85% Perf Quarter9.67%
Sales27.42B P/S3.30 EPS this Y-44.23% Inst Trans0.85% Short Ratio2.99 Perf Half Y-16.02%
Book/sh14.08 P/B5.15 EPS next Y90.49% ROA0.82% Short Interest23.00M Perf Year-8.11%
Cash/sh4.86 P/C14.92 EPS next 5Y5.38% ROE2.51% 52W Range62.07 - 87.86 Perf YTD-10.43%
Dividend Est.3.10 (4.27%) P/FCF11.44 EPS past 5Y1.55% ROI1.24% 52W High-17.42% Beta0.20
Dividend TTM3.04 (4.19%) Quick Ratio0.94 Sales past 5Y4.16% Gross Margin77.68% 52W Low16.90% ATR (14)1.66
Dividend Ex-DateJun 14, 2024 Current Ratio1.08 EPS Y/Y TTM-91.37% Oper. Margin34.04% RSI (14)66.59 Volatility2.49% 2.43%
Employees18000 Debt/Eq1.44 Sales Y/Y TTM2.13% Profit Margin1.77% Recom2.12 Target Price82.51
Option/ShortYes / Yes LT Debt/Eq1.23 EPS Q/Q-517.48% Payout66.62% Rel Volume0.72 Prev Close73.51
Sales Surprise5.17% EPS Surprise11.60% Sales Q/Q5.66% EarningsAug 08 AMC Avg Volume7.70M Price72.56
SMA204.42% SMA508.31% SMA200-1.29% Trades Volume5,569,587 Change-1.29%
Date Action Analyst Rating Change Price Target Change
Jul-08-24Upgrade Raymond James Mkt Perform → Outperform $93
May-01-24Reiterated Maxim Group Buy $90 → $85
Apr-24-24Upgrade HSBC Securities Reduce → Hold $69
Feb-22-24Downgrade Truist Buy → Hold $91 → $82
Nov-09-23Initiated Deutsche Bank Hold $75
Sep-08-23Upgrade BofA Securities Neutral → Buy $88 → $95
Sep-06-23Initiated HSBC Securities Reduce $71
Jul-24-23Reiterated Barclays Equal Weight $81 → $80
May-16-23Upgrade BMO Capital Markets Market Perform → Outperform $90 → $100
Apr-28-23Resumed Piper Sandler Overweight $105
Jul-18-24 05:45PM
09:00AM
Jul-17-24 08:50AM
07:15AM
05:52AM
06:00PM Loading…
Jul-16-24 06:00PM
08:30AM
Jul-15-24 07:34PM
10:51AM
Jul-14-24 06:30AM
Jul-13-24 11:00AM
Jul-11-24 10:30AM
Jul-10-24 06:00PM
Jul-09-24 06:00AM
Jul-08-24 12:03PM
09:08AM Loading…
09:08AM
Jul-04-24 02:13PM
10:01AM
Jul-03-24 06:00AM
Jul-02-24 03:17AM
Jul-01-24 08:45AM
06:55AM
06:50AM
Jun-27-24 03:28PM
Jun-25-24 06:00PM
Jun-23-24 01:38PM
Jun-21-24 03:43PM
03:43PM
12:58PM
09:41AM
09:17AM Loading…
09:17AM
09:14AM
08:45AM
07:34AM
07:10AM
06:31AM
03:39AM
Jun-20-24 05:35PM
05:06PM
04:21PM
04:16PM
04:09PM
04:06PM
03:14PM
02:49PM
12:40PM
12:24PM
12:12PM
09:00AM
08:51AM
08:45AM
07:30AM
Jun-19-24 09:15AM
Jun-17-24 04:02PM
03:27PM
Jun-14-24 04:19PM
02:27PM
07:01AM
03:00AM
Jun-13-24 06:00PM
Jun-12-24 09:00AM
Jun-08-24 06:50AM
Jun-07-24 05:50PM
11:36AM
11:35AM
Jun-06-24 09:00AM
04:45AM
04:30AM
Jun-05-24 09:45AM
09:15AM
07:55AM
07:00AM
06:40AM
05:06AM
04:25AM
02:00AM
Jun-04-24 03:57PM
06:15AM
Jun-03-24 04:26PM
04:17PM
01:59PM
10:00AM
09:00AM
Jun-02-24 08:00AM
Jun-01-24 08:00AM
May-31-24 01:01PM
12:18PM
08:07AM
07:01AM
04:25AM
May-30-24 04:45PM
May-29-24 02:02PM
06:05AM
May-28-24 09:50AM
09:45AM
May-27-24 12:32PM
May-25-24 11:10PM
May-22-24 05:17PM
10:48AM
08:30AM
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Parsey MerdadChief Medical OfficerJul 01 '24Sale68.632,000137,26096,380Jul 01 08:06 PM
GILEAD SCIENCES, INC.10% OwnerApr 02 '24Buy0.76485,250368,7907,345,473Apr 03 06:50 PM
Parsey MerdadChief Medical OfficerApr 01 '24Sale72.962,000145,92096,304Apr 02 06:38 PM
Parsey MerdadChief Medical OfficerFeb 29 '24Sale72.748,230598,62492,706Feb 29 06:35 PM
Parsey MerdadChief Medical OfficerFeb 28 '24Sale73.182,000146,360100,936Feb 29 06:35 PM
GILEAD SCIENCES, INC.10% OwnerFeb 12 '24Buy22.00910,00020,020,0004,126,119Feb 13 05:48 PM
GILEAD SCIENCES, INC.10% OwnerJan 29 '24Buy21.0015,238,095319,999,99530,061,124Jan 31 05:00 PM
Dickinson Andrew DChief Financial OfficerJan 16 '24Sale85.785,000428,900101,534Jan 17 06:01 PM
Mercier JohannaChief Commercial OfficerJan 09 '24Sale85.238,242702,46682,729Jan 10 03:58 PM
Dickinson Andrew DChief Financial OfficerOct 17 '23Sale80.005,000400,017104,003Oct 18 04:31 PM
Parsey MerdadChief Medical OfficerSep 12 '23Sale76.991,501115,56270,130Sep 13 06:50 PM